Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SJP-100
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : Sen-Jam Pharmaceutical
Deal Size : Undisclosed
Deal Type : Partnership
Sen-Jam Partners To Provide Manufacturing for Anti-Inflammatory Injectable
Details : KVK-Tech provides formulation and Manufacturing & Controls for Sen-Jam's first injectable anti-inflammatory therapeutic, SJP-100, which reduces inflammatory protein release from the immune system.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 04, 2024
Lead Product(s) : SJP-100
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : Sen-Jam Pharmaceutical
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Phentermine Hydrochloride
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Sponsor : Medix
Deal Size : Undisclosed
Deal Type : Partnership
KVK Tech’s Lomaira Completes Registration in Mexico Through Partner Medix
Details : Through the partnership, Medix will gain the exclusive rights to manufacture, distribute, and market Lomaira (Phentermine Hydrochloride) in Mexico. It is indicated for the treatment of obesity.
Product Name : Lomaira
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 31, 2024
Lead Product(s) : Phentermine Hydrochloride
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Sponsor : Medix
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Ketotifen Fumarate,Indomethacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : Sen-Jam Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SJP-002C (ketotifen) world most potent, orally available anti-inflammatory a person could obtain for a mild to moderate coronavirus infection, Sen-Jam's investigational therapeutic for treatment of COVID-19, SJP-002C is now actively enrolling patients fo...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 05, 2022
Lead Product(s) : Ketotifen Fumarate,Indomethacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : Sen-Jam Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketotifen Fumarate,Indomethacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : Sen-Jam Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
KVK Tech Announces Phase II Trial of COVID-19 Oral Therapy is Currently Enrolling in Nepal
Details : KVK will have exclusive manufacturing and supply rights for the product SJP-002C (Ketotifen) in the US. Sen-Jam will utilize the finished formulation and CMC report to enter licensing deals with contracting manufacturing companies (CMOs) globally.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 05, 2022
Lead Product(s) : Ketotifen Fumarate,Indomethacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : Sen-Jam Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Ketotifen Fumarate,Indomethacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Sen-Jam Pharmaceutical
Deal Size : Undisclosed
Deal Type : Partnership
Details : Sen-Jam Pharmaceutical has entered a development, manufacturing, distribution, and license agreement with KVK-Tech. This is a monumental milestone for the company and great news for their promising oral COVID-19 treatment, SJP-002C.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 22, 2022
Lead Product(s) : Ketotifen Fumarate,Indomethacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Sen-Jam Pharmaceutical
Deal Size : Undisclosed
Deal Type : Partnership